XML Financial LLC Buys 154 Shares of Amgen Inc. $AMGN

XML Financial LLC increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,269 shares of the medical research company’s stock after acquiring an additional 154 shares during the quarter. XML Financial LLC’s holdings in Amgen were worth $6,218,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC lifted its holdings in Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after acquiring an additional 5,226 shares in the last quarter. Fifth Third Wealth Advisors LLC lifted its holdings in shares of Amgen by 36.3% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 6,185 shares of the medical research company’s stock valued at $1,927,000 after purchasing an additional 1,647 shares in the last quarter. Mirador Capital Partners LP grew its position in shares of Amgen by 6.0% in the 1st quarter. Mirador Capital Partners LP now owns 1,116 shares of the medical research company’s stock valued at $348,000 after purchasing an additional 63 shares during the period. Fiduciary Alliance LLC increased its stake in Amgen by 0.9% during the 1st quarter. Fiduciary Alliance LLC now owns 29,168 shares of the medical research company’s stock worth $9,087,000 after purchasing an additional 262 shares in the last quarter. Finally, NBC Securities Inc. raised its holdings in Amgen by 111,133.3% during the 1st quarter. NBC Securities Inc. now owns 6,674 shares of the medical research company’s stock worth $2,079,000 after buying an additional 6,668 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Up 0.4%

Shares of Amgen stock opened at $273.97 on Tuesday. The stock has a market cap of $147.49 billion, a P/E ratio of 22.40, a P/E/G ratio of 2.37 and a beta of 0.49. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $335.88. The business’s 50 day moving average is $288.42 and its 200-day moving average is $288.61.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.28 by $0.74. The firm had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were issued a dividend of $2.38 per share. The ex-dividend date was Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a yield of 3.5%. Amgen’s dividend payout ratio (DPR) is presently 77.84%.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the sale, the senior vice president owned 7,209 shares in the company, valued at $2,141,000.91. This represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.69% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on AMGN shares. Raymond James Financial initiated coverage on shares of Amgen in a report on Wednesday, September 3rd. They issued a “market perform” rating for the company. William Blair reaffirmed an “outperform” rating on shares of Amgen in a research note on Tuesday, June 24th. Cantor Fitzgerald reissued a “neutral” rating and issued a $305.00 price target on shares of Amgen in a research note on Tuesday, June 24th. Morgan Stanley upped their price objective on Amgen from $330.00 to $333.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Finally, Bank of America lifted their target price on Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research report on Friday. Seven analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $309.70.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.